Cannabis Science, which recently announced that it would introduce a THC/CBD product for use in nebulizers by asthma/COPD patients, now says that it plans to market a metered dose inhaler called the CBIS MDI Rescue Inhaler “to prevent or treat an asthma/COPD attack.”
According to the company, the inhalers will be “100 – 200 dose MDI with cannabinoid level variations ranging from 10mg, 25mg, up to 100mg THC, CBD, and other cannabinoid variables as patient/consumer analysis moves further down the road.”
According to the announcement, Cannabis Science plans to market the MDI in the 25 US states where medical marijuana is legal. The company also said that its expects to receive the first batch of the product for nebulization within the next week and that it will be available in “select California dispensaries and available for delivery.”
Cannabis Science President and CEO Raymond C. Dabney commented, “We couldn’t be more excited to expand our company’s reach to impact more patients than ever in a positive way. It surprises people that cannabis can actually improve lung volume and air flow rates, but that’s exactly what studies show. We are glad to be one of the first to bring such an effective, natural treatment to market. The Cannabis Science Cannabinoid Based Inhalant will first be distributed in the State of California, but we plan to quickly roll the product out across the nation in legal states.”
In a separate announcement, the company said it “is happy to announce the intent to seek out 20 – 25 potential candidates suffering from Asthma/COPD and other critical ailments. These initial patients will receive the New MDI Inhalation device FREE for monitoring usage habits, combination levels, and tracking medical results. The observational study is being designed to accumulate valuable data to lead into clinical trials in the State of California.”
On this topic, Dabney said, “”We are already receiving inquiries from patients looking to be a part of a cannabinoid study targeting several critical ailments so we are responding to the inherent demand from the consumers. We believe we will get valuable feedback and clinical data from these participants that will aid us in establishing our products as an effective medication for these and other patients that suffer from so many different diseases. We are looking to have these patients in place by the time we launch and distribute this product to our partners and qualified legal vendors. We are very excited about this new product line and its potential to help these diminished lung function patients as well as the many other critical ailments we believe our cannabinoid formulations can help.”
Read the Cannabis Science MDI introduction press release.
Read the Cannabis Science MDI study press release.
